Vyome Holdings, Inc. (HIND)
Nasdaq · Healthcare · Biotechnology
$1.93+1.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $13.6M
- P/E (trailing)
- 1.1
- 52-week range
- $1.75 – $6.56
- 52-week change
- −69.24%
- EPS (trailing)
- $1.78
- Analyst rating
- 1.3 Strong buy
Fiscal year to Dec 2025
- Revenue
- $320K (+24.43%)
- Net income
- −$10.3M
- Operating margin
- −3269.5%
- Diluted EPS
- −$4.86
From the company’s annual report on SEC EDGAR.
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 9 employees · vyometx.com